Kasper R.
- Country
- Denmark
- Department
- The Heart Center
Research Overview
- A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization
- Phase 3 Randomized Double-Blind Study of NTLA-2001 Efficacy and Safety in Transthyretin Amyloidosis with Cardiomyopathy Patients
- Efficacy and Safety Evaluation of ALXN2220 in Adult Patients with Transthyretin Amyloid Cardiomyopathy: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Data & Insights
Has run more than one trial at 153 of 492 partner sites.
Specializations
Cardiac Amyloidosis Research
Specializes in investigating therapeutic approaches for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), with particular focus on innovative treatments including eplontersen and vutrisiran.
- ATTR-CM Management
- Long-term Safety Studies
- Amyloidosis Therapeutics
Explores both established and emerging treatment modalities for cardiac amyloidosis conditions.
Heart Failure Studies
Focuses on advanced treatments for heart failure with reduced ejection fraction (HFrEF) and investigates novel therapeutic agents including vericiguat for improving cardiac function.
- HFrEF Treatment Optimization
- Cardiac Function Assessment
- CardioMEMS Integration
Evaluates innovative approaches in heart failure management using advanced monitoring systems.
Pulmonary Hypertension Research
Investigates treatments for pulmonary hypertension due to left heart disease, with expertise in evaluating novel compounds for managing complex cardiovascular conditions.
- WHO Group 2 PH Studies
- Pulmonary Vascular Resistance
- Cardiovascular Therapeutics
Examines innovative therapeutic solutions for combined cardiac and pulmonary conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.